Advertisement

November 25, 2022

Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination with Chemotherapy: A Brief Report

  • Lindsey B. Shantzer,
  • Sean C. Dougherty,
  • Fabian Bolte,
  • ...
  • Ryan D. Gentzler,
  • Wendy Novicoff,
  • Richard D. Hall
Published online: November 25, 2022

Liquid Biopsy versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Luis E. Raez,
  • Kayla Brice,
  • Katerine Dumais,
  • ...
  • Paola A. Izquierdo,
  • Edgardo S. Santos,
  • Hermán W. Powery II
Published online: November 25, 2022

November 24, 2022

The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): real-world data on stage III non-small cell lung cancer patients treated with curative chemoradiation

  • Edith Dieleman,
  • Lisa van der Woude,
  • Rob van Os,
  • ...
  • Erwin Wiegman,
  • Ronald Damhuis,
  • Jose Belderbos
Published online: November 24, 2022
Open Access

November 20, 2022

Trends in Stage I Lung Cancer

  • Aashray Singareddy,
  • Mary Ellen Flanagan,
  • Pamela P Samson,
  • ...
  • Ramaswamy Govindan,
  • Varun Puri,
  • Daniel Morgensztern
Published online: November 20, 2022

November 18, 2022

Distinct prognostic impact of PET findings based on radiological appearance in clinical stage IA lung adenocarcinoma

  • Masayuki Nakao,
  • Takashi Terauchi,
  • Katsunori Oikado,
  • ...
  • Sakae Okumura,
  • Hironori Ninomiya,
  • Mingyon Mun
Published online: November 18, 2022

November 11, 2022

Implementation Challenges and Disparities in Molecular Testing for Patients with Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital

  • Laura Burns,
  • Chinmay Jani,
  • Amr Radwan,
  • ...
  • Mohini Patel,
  • Geoffrey R. Oxnard,
  • Umit Tapan
Published online: November 11, 2022

November 10, 2022

A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations

  • John Heymach,
  • Frans Opdam,
  • Minal Barve,
  • ...
  • Behbood Sadrolhefazi,
  • Josep Serra,
  • Noboru Yamamoto
Published online: November 10, 2022
Open Access

November 8, 2022

November 1, 2022

Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm

  • Jessica H. Tran,
  • Grace Mhango,
  • Henry S. Park,
  • ...
  • Qian Wang,
  • Juan P. Wisnivesky,
  • Rajwanth R. Veluswamy
Published online: November 01, 2022

Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report

  • Alexia Gazeu,
  • Mylena Aubert,
  • Daniel Pissaloux,
  • ...
  • Amine Bouhamama,
  • Tatiana Franceschi,
  • Aurélie Swalduz
Published online: November 01, 2022

October 20, 2022

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

  • G. Spitaleri,
  • P. Trillo Aliaga,
  • C. Catania,
  • ...
  • G. Curigliano,
  • A. Passaro,
  • F. de Marinis
Published online: October 20, 2022

October 13, 2022

A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer

  • Yang Yang,
  • Yanxiang Zhang,
  • Dandan Zhao,
  • Xiaoli Li,
  • Tonghui Ma
Published online: October 13, 2022
Open Access

October 12, 2022

Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series

  • Corrine A. Nief,
  • Hyunsoo Joshua No,
  • Christine Y. Louie,
  • Lucas Vitzthum,
  • Millie Das
Published online: October 12, 2022

Real-world ALK Testing Trends in Patients With Advanced Non–Small-Cell Lung Cancer in the United States

  • Huamao M. Lin,
  • Yanyu Wu,
  • Yu Yin,
  • ...
  • Eileen A. Curran,
  • Christine M. Lovly,
  • Michael J. Humphries
Published online: October 12, 2022

September 29, 2022

September 23, 2022

Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

  • Sabine Schmid,
  • Sierra Cheng,
  • Simren Chotai,
  • ...
  • Natasha B. Leighl,
  • Penelope A. Bradbury,
  • Geoffrey Liu
Published online: September 23, 2022

Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era

  • Amrit S. Gonugunta,
  • Mitchell S. Von Itzstein,
  • David Hsiehchen,
  • ...
  • Christopher Selby,
  • Carlos Alvarez,
  • David E. Gerber
Published online: September 23, 2022
Open Access

Increased Utilization of Stereotactic Body Radiotherapy is Associated with Decreased Disparities and Improved Survival for Early-Stage NSCLC

  • Ashwin Ganesh,
  • Mark Korpics,
  • Mary Pasquinelli,
  • Lawrence Feldman,
  • Michael Spiotto,
  • Matthew Koshy
Published online: September 23, 2022

August 29, 2022

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

  • Pierre Mordant MD, PhD,
  • Solenn Brosseau,
  • Bernard Milleron,
  • ...
  • Fabrice Barlesi,
  • Virginie Westeel
  • for the French Cooperative Thoracic Intergroup (IFCT)
Published online: August 29, 2022
Open Access

August 14, 2022

Pathological Stage N1 Limited-Stage Small-Cell Lung Cancer Patients Can Benefit From Surgical Resection

  • Lian Yu,
  • Jianlin Xu,
  • Rong Qiao,
  • Baohui Han,
  • Hua Zhong MD,
  • Runbo Zhong MD
Published online: August 14, 2022

Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy

  • Jing Fu,
  • Yuyang Tong,
  • Ziguang Xu,
  • ...
  • Tao Wang,
  • Cuidan Li,
  • Shundong Cang
Published online: August 14, 2022

December 24, 2021

November 10, 2020

WITHDRAWN: Progression patterns of metastatic lung adenocarcinoma patients with EGFR mutation

  • Shinichiro Okauchi,
  • Katsunori Kagohashi,
  • Toshihiro Shiozawa,
  • Kunihiko Miyazaki,
  • Hiroaki Satoh
Published online: November 10, 2020
Advertisement